Peptide vaccines for hematological malignancies: a missed promise? - Wikidata - awgldk - TriplyDB

Peptide vaccines for hematological malignancies: a missed promise?

Peptide vaccines for hematological malignancies: a missed promise?

http://www.wikidata.org/entity/Q38176546

about

Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation Identification of HLA‑A*1101‑restricted cytotoxic T lymphocyte epitopes derived from epidermal growth factor pathway substrate number 8.Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice.

P2860

Q35588845-E8C7E8A5-0885-47BA-B650-8C3BA3AE2953 Q37707523-0FB74D4A-BA49-484F-B43C-93A410AF1030 Q53394735-9D4A5C00-0BA9-4F8D-BE86-2762162896D7

P2860

Peptide vaccines for hematological malignancies: a missed promise?

http://www.wikidata.org/entity/Q38176546

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Peptide vaccines for hematological malignancies: a missed promise?

@en

type

label

Peptide vaccines for hematological malignancies: a missed promise?

@en

prefLabel

Peptide vaccines for hematological malignancies: a missed promise?

@en

P1433

Q38176546-62416D5D-A70C-40EE-ABD5-5CAA3B29776D

P1476

Q38176546-8D7DE104-DC99-480C-8F35-38F348CADDFB

P2093

Q38176546-6E28274A-832A-4516-AB57-519EB62E0E2F

Q38176546-6FA336ED-772B-4353-9417-5883FFAA1BFA

Q38176546-AE6486F0-888E-4EA0-95D5-FA15BEB38A62

P2860

Q38176546-11EBE23B-75CE-445A-9CD3-A48C11D748B0

Q38176546-15CC7F9A-597B-489B-A233-D2645507E7F2

Q38176546-17FCB3BD-DED9-4897-91A2-2E2CB66E3032

Q38176546-197D1727-9419-48A5-9C35-4F378078809E

Q38176546-21161F15-9AF7-4E2D-ABBD-9175E2CA38CE

Q38176546-225551F8-D59A-46F5-AD9E-095ECD396AD9

Q38176546-282E96B8-7C55-4B69-A81A-5ABA97656EDD

Q38176546-3A1846B9-857A-4A22-9F2F-A40856BED0D3

Q38176546-3A644FF4-7ACA-4FFE-8118-AA9647998F16

Q38176546-3CED4AAC-3BD5-46A1-9845-4EA90CDD566E

P2888

Q38176546-D71589C2-D8FC-42F2-9B05-2886C2253ED6

P304

Q38176546-58B96613-14E2-4592-96E7-22B29E39D1A4

P31

Q38176546-73EBA542-2724-4962-BB4E-DC8D45D8EBEA

P356

Q38176546-CF0023B6-3E63-44D6-B69D-DAA24EC0EF25

P433

Q38176546-C580E8CE-EC13-4C37-BA81-C2596A67573F

P478

Q38176546-1CF6848B-C61F-4523-8813-16364301742A

P50

Q38176546-67288BD3-3F17-42A8-B583-0C059EC5C400

P577

Q38176546-C94A7FE7-C1F4-4127-80E5-5767F0BE59FE

P5875

Q38176546-35110FC4-A660-4905-B49B-E450E0157DAB

P6179

Q38176546-3E418B4B-2934-4226-8DC9-CD375BA44CD1

P698

Q38176546-B4357726-0FA8-46D6-8C4E-44466BFF3ECD

P356

S12185-013-1497-3

P1433

International Journal of Hematology

P1476

Peptide vaccines for hematological malignancies: a missed promise?

@en

P2093

Anna Sicuranza

http://www.w3.org/2001/XMLSchema#string

Marzia Defina

http://www.w3.org/2001/XMLSchema#string

Monica Bocchia

http://www.w3.org/2001/XMLSchema#string

P2860

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma

Simultaneous expression of different immunogenic antigens in acute myeloid leukemia.

High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.

Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

Wilms' tumor gene WT1: its oncogenic function and clinical application.

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.

Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.

P2888

s12185-013-1497-3

P304

107-116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12185-013-1497-3

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259627228

http://www.w3.org/2001/XMLSchema#string

P6179

1052497657

http://www.w3.org/2001/XMLSchema#string

P698

24399190

http://www.w3.org/2001/XMLSchema#string